GILD
Gilead Sciences, Inc.
Drug Manufacturers - General · Healthcare · United States
138.14
close · 2026-08-13
value
45
cheaper than peers45
quality
50
stronger fundamentals50
ranked against
Healthcare
value
quality
374 peerssector comparisonwide variation
Value inputs
| measure | company | vs peers |
| forward P/E | 13.99× | 71 |
| EV to EBITDA | 12.19× | 67 |
| price to sales | 5.43× | 41 |
| price to book | 14.49× | 15 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 42.0% | 97 |
| revenue growth | 10.2% | 51 |
| return on equity | -20.7% | 45 |
| debt to equity | 226.5% | 12 |
4 of 4 measures available
Facts
| market cap | $171B |
| free cash flow | $12.17B |
| employees | 17,000 |
| first trade | 1992-01-22 |
| next earnings | 2026-08-04 |
| fundamentals updated | 2026-08-07 |